Since its founding in Columbia, Maryland, in 1998, Intralytix has built its identity around bacteriophage research and the precise control of harmful bacteria. The company is best known for pioneering the first FDA-cleared phage-based food additive, ListShield, in 2006, and now applies that technology to food safety and clinical-stage treatments for bacterial infections.
FDA GRAS
Compliance program
FDA CVM approval
Compliance program
FDA GRN 672
Compliance program
FDA GRN 435
Compliance program
FDA GRN 528
Compliance program
FDA GRN 834
Compliance program
FDA GRN 966
Compliance program
FDA 21 CFR 172.785
Compliance program
FSIS Directive 7120.1
Compliance program
Health Canada iLONO
Compliance program
Israel Ministry of Health Ref: 70275202
Compliance program
FDA CVM AGRN 74
Compliance program
SterilexFounded in 1994, Sterilex is a Hunt Valley, Maryland company best known for more than 30 years of work on biofilm removal and microbial control. Its science-backed sanitation chemistries serve customers seeking safer production and operating environments, particularly across food processing and animal health.HUNT VALLEY, MD
eEnzyme LLCFounded in 2004 and headquartered in Maryland, eEnzyme LLC develops research reagents, cell-based assay tools, and custom scientific solutions for life science laboratories worldwide. Its work is especially distinctive for combining infectious-disease research tools with ACTOne™ receptor cell lines, replication-deficient pseudovirus systems, and custom GPCR/PDE studies. eEnzyme supports academic, biotechnology, pharmaceutical, and government researchers from its Maryland operations.GAITHERSBURG, MD
K•D Medical, IncSince 1996, K•D Medical has been a woman-owned small business making research supplies in Columbia, Maryland. The company grew from a custom bacterial-media operation serving NIH researchers into a U.S. supplier of molecular biology products used by federal agencies, universities, and pharmaceutical companies.COLUMBIA, MD
Fzata, IncFzata, Inc. is a Maryland biotechnology company founded by scientists whose research focuses on C. difficile infection and the gut’s immune response. The near-clinical-stage company develops oral biologic medicines for gastrointestinal and immune-related disease, using its BioPYM platform to deliver treatments directly in the gut. Its work has attracted more than $24 million in non-dilutive NIH funding.HALETHORPE, MD